Vanguard Group’s Clovis Oncology, Inc. CLVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
|
|||||
|
2022
Q3 | $12.1M | Sell |
|
|||||
|
2022
Q2 | $20.2M | Sell |
|
|||||
|
2022
Q1 | $24.9M | Buy |
|
|||||
|
2021
Q4 | $27.4M | Sell |
|
|||||
|
2021
Q3 | $54.8M | Buy |
|
|||||
|
2021
Q2 | $57.5M | Buy |
|
|||||
|
2021
Q1 | $53.5M | Buy |
|
|||||
|
2020
Q4 | $30.7M | Buy |
|
|||||
|
2020
Q3 | $36M | Sell |
|
|||||
|
2020
Q2 | $42.2M | Buy |
|
|||||
|
2020
Q1 | $28.3M | Buy |
|
|||||
|
2019
Q4 | $44M | Sell |
|
|||||
|
2019
Q3 | $17.7M | Sell |
|
|||||
|
2019
Q2 | $68.1M | Sell |
|
|||||
|
2019
Q1 | $115M | Buy |
|
|||||
|
2018
Q4 | $81.9M | Buy |
|
|||||
|
2018
Q3 | $131M | Buy |
|
|||||
|
2018
Q2 | $197M | Buy |
|
|||||
|
2018
Q1 | $211M | Buy |
|
|||||
|
2017
Q4 | $267M | Buy |
|
|||||
|
2017
Q3 | $319M | Buy |
|
|||||
|
2017
Q2 | $339M | Buy |
|
|||||
|
2017
Q1 | $209M | Buy |
|
|||||
|
2016
Q4 | $116M | Buy |
|
|||||
|
2016
Q3 | $91M | Buy |
|
|||||
|
2016
Q2 | $33M | Buy |
|
|||||
|
2016
Q1 | $42.9M | Buy |
|
|||||
|
2015
Q4 | $78.2M | Buy |
|
|||||
|
2015
Q3 | $190M | Buy |
|
|||||
|
2015
Q2 | $158M | Buy |
|
|||||
|
2015
Q1 | $122M | Buy |
|
|||||
|
2014
Q4 | $78.3M | Buy |
|
|||||
|
2014
Q3 | $61.2M | Buy |
|
|||||
|
2014
Q2 | $55.6M | Buy |
|
|||||
|
2014
Q1 | $90.7M | Buy |
|
|||||
|
2013
Q4 | $75.7M | Buy |
|
|||||
|
2013
Q3 | $62.8M | Buy |
|
|||||
|
2013
Q2 | $49.8M | Buy |
|